9540 TOWNE CENTRE DRIVE, SAN DIEGO, CA
Bionano Genomics Elects Class II Directors at 2026 Annual Meeting
Reports First Quarter 2026 Results and Provides a Business Update
Announces Leadership Transition
Annual Report to Security Holders
Financial Results, Press Release
Reports Preliminary Fourth Quarter and Full-Year 2025 Results
Reports Third Quarter 2025 Results and Highlights Recent Business Progress
Announces Closing of $10 Million Public Offering
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(4)
S-1
Direct Registration System
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload